Nemoto K, Ogino M, Sugawara Y, Abe F, Ito J, Takeuchi T
Research Laboratories, Nippon Kayaku Co. LTD, Tokyo, Japan.
Br J Haematol. 1994 Jul;87(3):572-5. doi: 10.1111/j.1365-2141.1994.tb08314.x.
Deoxyspergualin (DGS) is a new immunosuppressant which has shown inhibitory haemopoietic activity. We investigated the myeloprotective effect of DSG against the haemopoietic injury of mitomycin C (MMC) or cyclophosphamide (CYC) by measuring peripheral blood cell numbers in dogs. DSG given at 5 mg/kg on days 3, 2 and 1 before, or at 10 mg/kg on either days 2 and 1 before or on day 1 before and the day of injection of MMC at 0.25 mg/kg ameliorated both the thrombocytopenia and leucopenia caused by MMC. This ameliorative effect was more evident on platelet counts than on white blood cell counts. In addition, the leucopenia and thrombocytopenia induced by a single injection of CYC at 10 mg/kg was also ameliorated by prior DSG administration. These findings suggest that DSG may be useful in protecting against the haemopoietic damage induced by chemotherapeutic agents in the treatment of cancer.
去氧精胍菌素（DGS）是一种新型免疫抑制剂，已显示出抑制造血的活性。我们通过测量犬外周血细胞数量，研究了DGS对丝裂霉素C（MMC）或环磷酰胺（CYC）所致造血损伤的骨髓保护作用。在注射0.25mg/kg MMC前3天、2天和1天给予5mg/kg的DGS，或在注射MMC前2天和1天或前1天及注射当天给予10mg/kg的DGS，均可改善MMC所致的血小板减少和白细胞减少。这种改善作用在血小板计数上比在白细胞计数上更明显。此外，预先给予DGS也可改善单次注射10mg/kg CYC所致的白细胞减少和血小板减少。这些发现表明，DGS可能有助于预防癌症治疗中化疗药物所致的造血损伤。
